MBX Biosciences Inc
MBX Biosciences Inc (MBX) Straddle
MBX straddle scan found 72 qualifying long straddle setups on the previous trading day. Probability of profit reaches up to 52.5%.
Read more
Trading a MBX straddle lets you take a pure volatility position on MBX Biosciences Inc without committing to a direction. MBX Biosciences Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate MBX straddle pricing in real time and find the moments when expected moves are mispriced.
A long straddle on MBX profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when MBX Biosciences Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the MBX straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.
In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Earnings, product cycles, macro prints — any time volatility itself is the trade, the MBX straddle is the cleanest expression of that view. Our scanner prices every MBX straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a MBX straddle into a catalyst or short a MBX straddle to harvest decay, the options straddle setups that matter are all in one place.
| Jan 21, 2028 | 105.00 | $63.50 | 490 | 6% | 52.5% | $168.50 | $41.50 | 0 |
| Jan 21, 2028 | 100.00 | $60.50 | 490 | 6% | 51.0% | $160.50 | $39.50 | 0 |
| Dec 18, 2026 | 105.00 | $46.05 | 91 | 6% | 50.2% | $151.05 | $58.95 | 0 |
| Jan 21, 2028 | 95.00 | $58.00 | 490 | 6% | 48.9% | $153.00 | $37.00 | 0 |
| Dec 18, 2026 | 100.00 | $42.10 | 91 | 6% | 48.6% | $142.10 | $57.90 | 0 |
| Apr 16, 2027 | 100.00 | $49.50 | 210 | 6% | 48.3% | $149.50 | $50.50 | 0 |
| Nov 20, 2026 | 80.00 | $22.60 | 63 | 6% | 48.1% | $102.60 | $57.40 | 0 |
| Jan 15, 2027 | 105.00 | $48.85 | 119 | 6% | 48.0% | $153.85 | $56.15 | 0 |
| Nov 20, 2026 | 85.00 | $26.83 | 63 | 6% | 47.8% | $111.83 | $58.18 | 0 |
| Jan 21, 2028 | 90.00 | $55.00 | 490 | 6% | 47.4% | $145.00 | $35.00 | 2 |
As of September 18, 2026
Find the right straddle before volatility moves
Track MBX straddle pricing across expirations, filter by IV rank and breakeven points, and build a setup that fits your view before the move happens.
Start your 14-day free trial→